Excessive Apoptosis in Low Risk Myelodysplastic Syndromes (MDS)

References

• Kerr J.F.R., Wyllie A. H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer 1972; 26: 239–257
   PubMed Web of Science ®Google Scholar
• Yoshida Y. Hypothsis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 1993; 1: 144–146
   Google Scholar
• Raza A., Gezer S., Mundle S., Gao X. Z., Alvi S., Borok R., Rifkin S., Iftikhar A., Shetty V., Parcharidou A., Loew J., Marcus B., Khan Z., Chaney C., Showel J., Gregory S., Preisler H. Apoptois in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268–276
   PubMed Web of Science ®Google Scholar
• Fadok V. A., Voelker D. R., Campbell P. A., Cohen J. J., Bratton D. L., Henson P. M. Exposue of phos-phatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. Journal of Immunology 1992; 148: 2207–2216
   PubMed Web of Science ®Google Scholar
• Martin S. J., Cotter TG. Ultraviolet B irradiation of human leukemia HL-60 cells in vitro induces apoptosis. International Journal of Radiation Biology 1991; 59: 1001–1016
   PubMed Web of Science ®Google Scholar
• Hickman J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Reviews 1992; 11: 121–139
   PubMed Web of Science ®Google Scholar
• Laster S. M., Wood J. G., Gooding L. R. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. Journal of Immunology 1988; 141: 2629–2634
   PubMed Web of Science ®Google Scholar
• Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169–1178
   PubMed Web of Science ®Google Scholar
• Williams G. T., Smith C. A., Spooncer E., Dexter T. M., Taylor D. R. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 1990; 343: 76–79
   PubMed Web of Science ®Google Scholar
• Thornberry N. A., Lazebnik Y. Caspases: Enemies within. Science 1998; 281: 1312–1316
   PubMed Web of Science ®Google Scholar
• Alnemri E. S., Livingston D. J., Nicholson D. W., Salvesen G., Thornberry N. A., Wong W. W., Yuan J. Human ICE/CED-3 protease nomenclature. Cell 1996; 87: 171
   PubMed Web of Science ®Google Scholar
• Van De Craen M., Van Loo G., Pype S., Van Criekinge W., Van Den Brande I., Molemans E., Fiers W., Declercq W., Vandenabeele P. Identification of a new cas-pase homologue: caspase-14. Cell Death and Differentiation 1998; 5: 838–846
   PubMed Web of Science ®Google Scholar
• Slee E. A., Harte M. T., Kluck R. M., Wolf B. B., Casiano C. A., Newmeyer D. D., Wang H. G., Reed J. C., Nicholson D. W., Alnemri E. S., Green D. R., Martin S. J. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. Journal of Cell Biology 1999; 144: 281–292
   PubMed Web of Science ®Google Scholar
• Muzio M., Chinnaiyan A. M., Kischkel EC., O'Rourke K., Shevchenko A., Ni J., Scaffidi C., Bretz J. D., Zhang M., Gentz R., Mann M., Krammer P. H., Peter M. E., Dixit V. M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817–827
   PubMed Web of Science ®Google Scholar
• Boldin M. P., Goncharov T. M., Goltsev Y. V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996; 85: 803–815
   PubMed Web of Science ®Google Scholar
• Li P., Nijhawan D., Budihardjo I., Srinivasula S. M., Ahmad M., Alnemri E. S., Wang X. Cytochome c and dATP-dependent formation of Apaf-1/cas-pase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479–489
   PubMed Web of Science ®Google Scholar
• Pan G., Humke E. W., Dixit V.M. Activation of caspases triggered by cytochrome c in vitro. FEES Letters 1998; 426: 151–154
   PubMed Web of Science ®Google Scholar
• Nakagawa T., Zhu H., Morishima N., Li E., Xu J., Yankner B. A., Yuan J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000; 403: 98–103
   PubMed Web of Science ®Google Scholar
• Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A. caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391: 43–50
   PubMed Web of Science ®Google Scholar
• Liu X., Li P., Widlak P., Zou H., Luo X., Garrard W. T., Wang X. (1978) The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proceedings of the National Academy of Sciences of the United States of America 1998; 95:8461–8466. 1998
   Google Scholar
• Earnshaw W. C., Martins L. M., Kaufmann S. H. Mammalian caspases: Structure, activation, substrates and functions during apoptosis. Ann Rev Biochemistry 1999; 68: 383
   PubMed Web of Science ®Google Scholar
• Nagata S., Golstein P. The Fas death factor. Science 1995; 267: 1449–1456
   PubMed Web of Science ®Google Scholar
• Itoh N., Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. Journal of Biological Chemistry 1993; 268: 10932–10937
   PubMed Web of Science ®Google Scholar
• Banner D. W., D'Arcy A., Janes W., Gentz R., Schoenfeld H. J., Broger C., Loetscher H., Lesslauer W. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73: 431–435
   PubMed Web of Science ®Google Scholar
• Chinnaiyan A. M., O'Rourke K., Tewari M., Dixit V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505–512
   PubMed Web of Science ®Google Scholar
• Hsu H., Xiong J., Goeddel D. V. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995; 81: 495–504
   PubMed Web of Science ®Google Scholar
• Hsu H., Huang J., Shu H. B., Baichwal V., Goeddel D.V. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996; 4: 387–396
   PubMed Web of Science ®Google Scholar
• Hsu H., Shu H. B., Pan M. G., Goeddel D. V. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84: 299–308
   PubMed Web of Science ®Google Scholar
• Imai Y., Kimura T., Murakami A., Yajima N., Sakamaki K., Yonehara S. The CED-4-homologous protein FLASH is involved in Fas-mediated activation of cas-pase-8 during apoptosis. Nature 1999; 398: 777–785
   PubMed Web of Science ®Google Scholar
• Binder C., Schulz M., Hiddemann W., Oellerich M. Capsase activation and induction of inducible nitric oxide-synthase during TNF alpha-triggered apoptosis. Anticancer Research 1999; 19: 1715–1720
   PubMed Web of Science ®Google Scholar
• Berke G. The CTL's kiss of death. Cell 1995; 81: 9
   PubMed Web of Science ®Google Scholar
• Froelich C. J., Dixit V. M., Yang X. Lymphocyte granule-mediated apoptosis: Matters of viral mimicry and deadly proteases. Immunology Today 1998; 19: 30–36
   PubMedGoogle Scholar
• Kroemer G., Zamzami N., Susin S. A. Mitochondrial control of apoptosis. Immunology Today 1997; 18: 44–51
   PubMedGoogle Scholar
• Marchetti P., Castedo M., Susin S. A., Zamzami N., Hir-Sch T., Macho A., Haeffner A., Hirsch E., Geuskens M., Kroemer G. Mitochondrial permeability transition is a central coordinating event of apoptosis. Journal of Experimental Medicine 1996; 184: 1155–1160
   PubMed Web of Science ®Google Scholar
• Skulachev V. P. Why are mitochondria involved in apoptosis? Permeability transition pores and apoptosis as selective mechanisms to eliminate superoxide-producing mitochondria and cell. FEBS Letters 1996; 397: 7–10
   PubMed Web of Science ®Google Scholar
• Liu X., Kim C. N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86: 147–157
   PubMed Web of Science ®Google Scholar
• Zou H., Henzel W. J., Liu X. S., Lutschg A., Wang X. D. Apaf-1, a human protein homologous to C-ele-gans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405–413
   PubMed Web of Science ®Google Scholar
• Vander Heiden M.G., Chandel N. S., Williamson E. K., Schumacker P. T., Thompson C.B. Bcl-XL regulates the membrane potential and volume homeostasis of mitochondria. Cell 1997; 91: 627–637
   PubMed Web of Science ®Google Scholar
• Mancini M., Nicholson D. W., Roy S., Thornberry N. A., Peterson E. P., Casciola-Rosen L.A., Rosen A. The caspase-3 precursor has a cytosolic and mitochondrial distribution: implications for apoptotic signaling. Journal of Cell Biology 1998; 140: 1485–1495
   PubMed Web of Science ®Google Scholar
• Susin S. A., Lorenzo H. K., Zamzami N., Marzo I., Brenner C., Larochette N., Prevost M. C., Alzari P. M., Kroemer G. Mitochondrial release of caspase-2 and -9 during the apoptotic process. Journal of Experimental Medicine 1999; 189: 381–394
   PubMed Web of Science ®Google Scholar
• Susin S. A., Lorenzo H. K., Zamzami N., Marzo I., Snow B. E., Brothers G. M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D. R., Aebersold R., Siderovski D. P., Penninger J. M., Kroemer G. Molecular characterization of mitochondrial apop-tosis-inducing factor. Nature 1999; 397: 441–446
   PubMed Web of Science ®Google Scholar
• Lorenzo H. K., Susin S. A., Penninger J. M., Kroemer G. Apoptosis-inducing factor (AIF) a phylogeneti-cally old, caspase-independentt effector of cell death. Cell Death and Differentiation 1999; 6: 516–524
   PubMed Web of Science ®Google Scholar
• Yang E., Korsmeyer S. J. Molecular thanatop-sis: a discourse on the BCL2 family and cell death. Blood 1996; 88: 386–401
   PubMed Web of Science ®Google Scholar
• Jacobson M. D., Burne J. F., King M. P., Miyashita T., Reed J. C., Raff M. C. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 1993; 361: 365–369
   PubMed Web of Science ®Google Scholar
• Muchmore S. W., Sattler M., Liang H., Meadows R. P., Harlan J. E., Yoon H. S., Nettesheim D., Chang B. S., Thompson C. B., Wong S. L., Ng S. L., Fesik S. W. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381: 335–341
   PubMed Web of Science ®Google Scholar
• Schendel S. L., Xie Z. H., Montal M. O., Matsuyama S., Montal M., Reed J. C. (1978) Channel formation by antiapoptotic protein Bcl-2. Proceedings of the National Academy of Sciences of the United States of America 1997; 94:5113–5118. 1997
   Google Scholar
• Minn A. J., Velez P., Schendel SL., Liang H., Muchmore SW., Fesik S. W., Fill M., Thompson C. B. Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature 1997; 385: 353–357
   PubMed Web of Science ®Google Scholar
• Jurgensmeier J. M., Xie Z., Deveraux Q., Ellerby L., Bredesen D., Reed J. C. (1978) Bax directly induces release of cytochrome c from isolated mitochondria. Proceedings of the National Academy of Sciences of the United States of America 1998; 95:4997–5002. 1998
   Google Scholar
• Hsu Y-T, Wolter K.G, Youle R. J. (1978) Cytosol-to-membrane redistribution of Bax and Bcl-XL during apoptosis. Proceedings of the National Academy of Sciences of the United States of America 1997; 94:3668. 1997
   Google Scholar
• Wolter K. G., Hsu Y-T, Smith C. L., Nechushtan A., Xi X-G., Youle R. J. Movement of Bax from the cytosol to mitochondria during apoptosis. Journal of Cell Biology 1997; 119: 1281–1292
   Web of Science ®Google Scholar
• Griffiths G. J., Dubrez L., Morgan C. P., Jones N. A., Whitehouse J., Corfe B. M., Dive C., Hickman J. A. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. Journal of Cell Biology 1999; 144: 903–914
   PubMed Web of Science ®Google Scholar
• Desagher S., Osen-Sand A., Nichols A., Eskes R., Mon-Tessuit S., Lauper S., Maundrell K., Antonsson B., Martinou J. C. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. Journal of Cell Biology 1999; 144: 891–901
   PubMed Web of Science ®Google Scholar
• Zha J., Harada H., Yang E., Jockel J., Korsmeyer S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-XL. Cell 1996; 87: 619–628
   PubMed Web of Science ®Google Scholar
• Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609–619
   PubMed Web of Science ®Google Scholar
• Reed J. C. Double identity for proteins of the Bcl-2 family. Nature 1997; 387: 773–776
   PubMed Web of Science ®Google Scholar
• Kharbanda S., Pandey P., Schofield L., Israels S., Roncinske R., Yoshida K., Bharti A., Yuan Z. M., Saxena S., Weichselbaum R., Nalin C., Kufe D. (1978) Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America Proc Natl Acad Sc USA 1997; 94:6939–6942. 1997
   Google Scholar
• Hu Y., Benedict M. A., Wu D., Inohara N., Nunez G. (1978) Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proceedings of the National Academy of Sciences of the United States of America 1998; 95:4386–4391. 1998
   Google Scholar
• Shibasaki F., McKeon F. Calcineurin functions in Ca(2+)-activated cell death in mammalian cells. Journal of Cell Biology 1995; 131: 735–743
   PubMed Web of Science ®Google Scholar
• Naumovski L., Cleary M. L. The p53-binding protein 53BP2 also interacts with Be 12 and impedes cell cycle progression at G2/M. Molecular Cell Biology 1996; 16: 3884–3892
   PubMed Web of Science ®Google Scholar
• Wang H. G., Rapp U. R., Reed J. C. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629–638
   PubMed Web of Science ®Google Scholar
• Sheridan J. P., Marsters S. A., Pitti R. M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C. L., Baker K., Wood W. I., Goddard A. D., Godowski P., Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818–821
   PubMed Web of Science ®Google Scholar
• Pan G., Ni J., Wei Y. F., Yu G., Gentz R., Dixit V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815–818
   PubMed Web of Science ®Google Scholar
• Macfarlane M., Ahmad M., Srinivasula S. M., Fern-Andes-Alnemri T., Cohen G. M., Alnemri E. S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. Journal of Biological Chemistry 1997; 272: 25417–25420
   PubMed Web of Science ®Google Scholar
• Marsters S. A., Sheridan J. P., Pitti R. M., Huang A., Skubatch M., Baldwin D., Yuan J., Gurney A., Goddard A. D., Godowski P., Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Current Biology 1997; 1: 1003–1006
   Web of Science ®Google Scholar
• Schneider P., Bodmer J. L., Thome M., Hofmann K., Holler N., Tschopp J. Characterization of two receptors for TRAIL. FEBS Letters 1997; 416: 329–334
   PubMed Web of Science ®Google Scholar
• Emery J. G., McDonnell P., Burke M. B., Deen K. C., Lyn S., Silverman C., Dul E., Appelbaum E. R., Eichman C., Diprinzio R., Dodds R. A., James I. E., Rosenberg M., Lee J. C., Young P. R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Journal of Biological Chemistry 1998; 273: 14363–14367
   PubMed Web of Science ®Google Scholar
• Pitti R. M., Marsters S. A., Lawrence D. A., Roy M., Kischkel F. C., Dowd P., Huang A., Donahue C. J., Sherwood S. W., Baldwin D. T., Godowski P. J., Wood W. I., Gurney A. L., Hillan K. J., Cohen R. L., Goddard A. D., Botstein D., Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699–703
   PubMed Web of Science ®Google Scholar
• Jiang Y., Woronicz J. D., Liu W., Goeddel D. V. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 1999; 283: 543–546
   PubMed Web of Science ®Google Scholar
• Condorelli G., Vigliotta G., Cafieri A., Trencia A., Andalo P., Oriente R., Miele C., Caruso M., Formisano P., Beguinot F. PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. Oncogene 1999; 18: 4409–4415
   PubMed Web of Science ®Google Scholar
• Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J. L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L. E., Tschopp J., Thome M. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190–195
   PubMed Web of Science ®Google Scholar
• Srinivasula S. M., Ahmad M., Ottilie S., Bullrich E., Banks S., Wang Y., Fernandes-Alnemri T., Croce CM., Litwack G., Tomaselli K. J., Armstrong R. C., Alnemri E. S. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. Journal of Biological Chemistry 1997; 212: 18542–18545
   Web of Science ®Google Scholar
• Kumar A., Commane M., Flickinger T. W., Horvath CM., Stark G. R. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1997; 278: 1630–1632
   PubMed Web of Science ®Google Scholar
• Duckett C. S., Nava V. E., Gedrich R. W., Clem R. J., Van Dongen J.L., Gilfillan M. C., Shiels H., Hardwick J. M., Thompson C. B. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO Journal 1996; 15: 2685–2694
   PubMed Web of Science ®Google Scholar
• Liston P., Roy N., Tamai K., Lefebvre C., Baird S., Cherton-Horvat G., Farahani R., McLean M., Ikeda J. E., Mackenzie A., Korneluk R. G. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996; 379: 349–353
   PubMed Web of Science ®Google Scholar
• Uren A. G., Pakusch M., Hawkins C. J., Puis K. L., Vaux D. L. (1978) Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proceedings of the National Academy of Sciences of the United States of America 1996; 93:4974–4978. 1996
   Google Scholar
• Deveraux Q. L., Roy N., Stennicke H. R., Van Arsdale T., Zhou Q., Srinivasula S. M., Alnemri E. S., Salvesen G. S., Reed J. C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO Journal 1998; 17: 2215–2223
   PubMed Web of Science ®Google Scholar
• Deveraux Q. L., Takahashi R., Salvesen G. S., Reed J. C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300–304
   PubMed Web of Science ®Google Scholar
• Roy N., Deveraux Q.L, Takahashi R., Salvesen G. S., Reed J. C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO Journal 1997; 16: 6914–6925
   PubMed Web of Science ®Google Scholar
• Tamm I., Wang Y., Sausville E., Scudiero D. A., Vigna N., Oltersdorf T., Reed J. C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Research 1998; 58: 5315–5320
   PubMed Web of Science ®Google Scholar
• Srinivasula S. M., Ahmad M., Guo Y., Zhan Y., Lazebnik Y., Fernandes-Alnemri T., Alnemri E. S. Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. Cancer Research 1999; 59: 999–1002
   PubMed Web of Science ®Google Scholar
• Seol D. W., Billiar T. R. A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. Journal of Biological Chemistry 1999; 274: 2072–2076
   PubMed Web of Science ®Google Scholar
• Grana X., Reddy E. P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995; 11: 211–219
   PubMed Web of Science ®Google Scholar
• Sherr C. J. Mammalian G1 cyclins. Cell 1993; 73: 1059–1065
   PubMed Web of Science ®Google Scholar
• Kato J., Matsushime H., Hiebert S. W., Ewen M. E., Sherr C. J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes and Development 1993; 7: 331–342
   PubMed Web of Science ®Google Scholar
• Lam E. W., La T. N. DP and E2F proteins: coordinating transcription with cell cycle progression. Current Opinion in Cell Biology 1994; 6: 859–866
   PubMed Web of Science ®Google Scholar
• Johnson D. G., Schwarz J. K., Cress W. D. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993; 365: 349–352
   PubMed Web of Science ®Google Scholar
• Helin K., Harlow E., Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Molecular Cell Biology 1993; 13: 6501–6508
   PubMed Web of Science ®Google Scholar
• Levine AJ. p53, the cellular gatekeeper for growth and cell division. Cell 1997; 88: 323–331
   PubMed Web of Science ®Google Scholar
• Lin D., Shields M. T., Ullrich S. J., Appella E., Mercer W. E. (1978) Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proceedings of the National Academy of Sciences of the United States of America 1992; 89:9210–9214. 1992
   Google Scholar
• El Deiry W.S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825
   PubMed Web of Science ®Google Scholar
• Miyashita T., Krajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D. A., Hoffman B., Reed J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799–1805
   PubMed Web of Science ®Google Scholar
• Owen-Schaub L.B., Zhang W., Cusack J.C, Angelo L. S., Santee S. M., Fujiwara T., Roth J. A., Deisseroth A. B., Zhang W. W., Kruzel E., Radinsky R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Molecular Cell Biology 1995; 15: 3032–3040
   PubMed Web of Science ®Google Scholar
• Polyak K., Xia Y., Zweier J. L., Kinzler K. W., Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300–305
   PubMed Web of Science ®Google Scholar
• Barak Y., Juven T., Haffner R., Oen M. mdm2 expression is induced by wild type p53 activity. EMBO Journal 1993; 12: 461–468
   PubMed Web of Science ®Google Scholar
• Jost C. A., Marin M. C., Kaelin W. G. p73 is a human p53-related protein that can induce apoptosis. Nature 1997; 389: 191–194
   PubMed Web of Science ®Google Scholar
• Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J. C., Valent A., Minty A., Chalon P., Lelias J. M., Dumont X., Ferrara P., McKeon F., Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809–819
   PubMed Web of Science ®Google Scholar
• Yang A., Kaghad M., Wang Y., Gillett E., Fleming M. D., Dotsch V., Andrews N. C., Caput D., McKeon F. p63. a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305–316
   PubMed Web of Science ®Google Scholar
• Clark D. M., Lampert I. A. Apoptosis is a common histopathological finding in myelodysplasia: The correlate of ineffective haematopoiesis. Leukemia Lymphoma 1990; 2: 415–418
   PubMed Web of Science ®Google Scholar
• Ohmori M., Ohmori S., Ueda Y., Yoshida Y, Okuma M. Ineffective hematopoiesis in the myelodysplastic syndromes (MDS) as studied by daily in situ observation of colony-cluster formation. International Journal of Cell Cloning 1991; 9: 521–530
   PubMedGoogle Scholar
• Rajapaksa R., Ginzton N., Rott L. S., Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88: 4275–4287
   PubMed Web of Science ®Google Scholar
• Bogdanovic A. D., Trpinac D.P, Jankovic G. M., Bum-Basirevic V.Z., Obradovic M., Colovic M. D. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 1997; 11: 656–689
   PubMed Web of Science ®Google Scholar
• Parker J. E., Fishlock K. L., Czepulkowski B., Mijovic A., Pagliuca A., Mufti G. J. 'Low risk' Myelodysplastic Syndrome (MDS) is associated with excessive apoptosis and an increased ratio of pro- versus anti- apop-totic Bcl-2 related proteins. British Journal of Haematology 1998; 103: 1075–1082
   PubMed Web of Science ®Google Scholar
• Anzai N., Kawabata H., Hirama T., Masutani H., Ohmori M., Yoshida Y., Okuma M. Marked apoptosis of human myelomonocytic cell line P39. Significance of cellular differentiation. Leukemia 1994; 8: 446–453
   PubMed Web of Science ®Google Scholar
• Bouscary D., De Vos J., Guesnu M., Jondeau K., Viguier F., Melle J., Picard F., Dreyfus F., Fontenay-Roupie M. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997; 11: 839–845
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E., Kanter-Lewensohn L., Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leukemia Research 1997; 21: 415–425
   PubMed Web of Science ®Google Scholar
• Ormerod M. G. Analysis of DNA. General methods. Flow Cytometry. A Practical Approach, MG Ormerod. IRL press at Oxford University Press, Oxford 1990; 69
   Google Scholar
• Tsoplou P., Kouraklis-Symeonidis A., Thanopoulou E., Zikos P., Orphanos V., Zoumbos N. Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes. Leukemia 1999; 13: 1554–1563
   PubMed Web of Science ®Google Scholar
• Darzynkiewicz Z., Bedner E., Traganos F, Murakami T. Critical aspects in the analysis of apoptosis and necrosis. Human Cell 1998; 11: 3–12
   PubMedGoogle Scholar
• Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leukemia Research 1998; 22: 1123–1136
   PubMed Web of Science ®Google Scholar
• Yaguchi M., Miyazawa K., Otawa M., Katagiri T., Nishi-Maki J., Uchida Y., Iwase O., Gotoh A., Kawanishi Y, Toyama K. Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptotic cells using APO2.7 monoclonal antibody. Leukemia 1998; 12: 1392–1397
   PubMed Web of Science ®Google Scholar
• Koopman G., Reutelingsperger C. P., Kuijten G. A., Keehnen R. M., Pals S. T., Van-Oers M.H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415–1420
   PubMed Web of Science ®Google Scholar
• Vermes I., Haanen C., Steffens-Nakken H., Reuteling-Sperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. Journal of Immunological Methods 1995; 184: 39–51
   PubMed Web of Science ®Google Scholar
• Greenberg P., Cox C., Lebeau M. M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Marsh J. C., Chang J., Testa N. G., Hows J. M., Dexter T. M. In vitro assessment of marrow 'stem cell' and stromal cell function in aplastic anaemia. British Journal of Haematology 1991; 78: 258–267
   PubMed Web of Science ®Google Scholar
• Asano H., Hotta T., Ichihara M., Murate T., Kobayashi M., Saito H. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes. Leukemia 1994; 8: 833–838
   PubMed Web of Science ®Google Scholar
• Silverman L. R., Zinzar S., Holland J. F. Biological consequences of stromal abnormalities in the myelodysplastic syndrome (MDS) its influence on the hematopoietic dysregulation. Leukemai Research 1997; 21: S20
   Google Scholar
• Aizawa S., Nakano M., Iwase O., Yaguchi M., Hiramoto M., Hoshi H., Nabeshima R., Shima D., Handa H., Toyama K. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leukemia Research 1999; 23: 239–246
   PubMed Web of Science ®Google Scholar
• List A. F., Glinsmann-Gibson B., Spier C., Taetle R. In vitro and in vivo response to cyclosporin-A in myelodysplastic syndromes: Identification of a hypocellu-lar subset responsive to immune suppression. Blood 1992; 80: 28a
   Google Scholar
• Goossens V., Grooten J., De Vos K., Fiers W. (1978) Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America 1995; 92:8115–8119. 1995
   Google Scholar
• Peddie CM., Wolf R., McLellan L. I., Collins A. R., Bowen D. T. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-α concentration. British Journal of Haematology 1997; 99: 625–631
   PubMed Web of Science ®Google Scholar
• Dreher D., Junod A. F. Role of oxygen-free radicals in cancer development. European Journal of cancer 1996; 32A: 30
   PubMed Web of Science ®Google Scholar
• Lyons J., Janssen J. W., Bartram C., Layton M., Mufti G. J. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Blood 1988; 71: 1707–1712
   PubMed Web of Science ®Google Scholar
• Ridge S. A., Worwood M., Oscier D., Jacobs A., Padua R. A. (1978) FMS mutations in myelodysplastic, leukemic, and normal subjects. Proceedings of the National Academy of Sciences of the United States of America 1990; 87:1377–1380. 1990
   Google Scholar
• Verhoef G. E., De Schouwer P., Ceuppens J. L., Van Damme J., Goossens W., Boogaerts M. A. Van Damme J., Goossens W., Boogaerts MA Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992; 6: 1268–1272
   PubMed Web of Science ®Google Scholar
• Kitagawa M., Saito I., Kuwata T., Yoshida S., Yamaguchi S., Takahashi M., Tanizawa T., Kamiyama R., Hirokawa K. Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049–2054
   PubMed Web of Science ®Google Scholar
• Gersuk G. M., Beckham C., Loken M. R., Kiener P., Anderson J. E., Farrand A., Troutt A. B., Ledbetter J. A., Deeg H. J. A role for tumour necrosis factor-α, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. British Journal of Haematology 1998; 103: 176–188
   PubMed Web of Science ®Google Scholar
• Mundle S. D., Reza S., Ali A., Mativi Y., Shetty V., Venugopal P., Gregory S. A., Raza A. Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Letters 1999; 140: 201–207
   PubMed Web of Science ®Google Scholar
• Maciejewski J., Selleri C., Anderson S., Young N. S. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995; 85: 3183–3196
   PubMed Web of Science ®Google Scholar
• Kitagawa M., Yamaguchi S., Takahashi M., Tanizawa T., Hirokawa K., Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998; 12: 486–492
   PubMed Web of Science ®Google Scholar
• Lepelley P., Grardel N., Envy O., Iaru T., Obein V., Cos-Son A., Fenaux P. Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leukemia Lymphoma 1998; 30: 307–312
   PubMed Web of Science ®Google Scholar
• O'Connell J., O'Sullivan G.C., Collins J. K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. Journal of Experimental Medicine 1996; 184: 1075–1082
   PubMed Web of Science ®Google Scholar
• Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363–1366
   PubMed Web of Science ®Google Scholar
• Gupta P., Niehans G. A., Leroy S. C., Gupta K., Morrison V. A., Schultz C., Knapp D. J., Kratzke R. A. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia 1999; 13: 44–53
   PubMed Web of Science ®Google Scholar
• Krajewska M., Krajewski S., Epstein J. I., Shabaik A., Sauvageot J., Song K., Kitada S., Reed J. C. Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancers. American Journal of Pathology 1996; 148: 1567–1576
   PubMed Web of Science ®Google Scholar
• Ter-Harmsel B., Smedts F., Kuijpers J., Jeunink M., Trimbos B., Ramaekers F. BCL-2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelia, CIN, and cervical carcinoma. Journal of Pathology 1996; 179: 26–30
   PubMed Web of Science ®Google Scholar
• Agular-Santelises M., Rottenberg M. E., Lewin N., Mell-Stedt H., Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. International Journal of Cancer 1996; 69: 114–119
   PubMed Web of Science ®Google Scholar
• Pepper C., Hoy T., Bentley D. P. Bcl-2/Bax ratios in chonic lymphocytic lelukaemia and their correlation with in vitro apoptosis and clinical resistance. British Journal of Cancer 1997; 76: 935–938
   PubMed Web of Science ®Google Scholar
• Meijerink J. P., Smetsers T. F., Sloetjes A. W., Linders E. H., Mensink E. J. Bax mutations in cell lines derived from hematological malignancies. Leukemia 1995; 9: 1828–1832
   PubMed Web of Science ®Google Scholar
• Davis R. E., Greenberg P. L. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leukemia Research 1998; 22: 767–777
   PubMed Web of Science ®Google Scholar
• Hunter T., Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573–582
   PubMed Web of Science ®Google Scholar
• Jiang W., Zhang Y. J., Kahn S. M., Hollstein M. C., San-Tella R.M., Lu S. H., Harris C. C., Montesano R., Wein-Stein LB. (1978) Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proceedings of the National Academy of Sciences of the United States of America 1993; 90:9026–9030. 1993
   Google Scholar
• Paggi M. G., Baldi A., Bonetto F., Giordano A. Retinoblastoma protein family in cell cycle and cancer: a review. Journal of Cell Biochemistry 1996; 62: 418–430
   PubMed Web of Science ®Google Scholar
• Preudhomme C., Vachee A., Lepelley P., Vanrumbeke M., Zandecki M., Quesnel B., Cosson A., Fenaux P. Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. British Journal of Haematology 1994; 87: 61–67
   PubMed Web of Science ®Google Scholar
• Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., III., Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436–440
   PubMed Web of Science ®Google Scholar
• Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753–756
   PubMed Web of Science ®Google Scholar
• Hirama T., Koeffler H. P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841–854
   PubMed Web of Science ®Google Scholar
• Herman J. G., Jen J., Merlo A., Baylin S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Research 1996; 56: 722–777
   PubMed Web of Science ®Google Scholar
• Herman J. G., Civin C. I., Issa J.P.J., Collector M. I., Sharkis S. J., Baylin S. B. Distinct patterns of inactivation of p15 4B and p16INK4A characterize the major types of hematological malignancies. Cancer Research 1997; 57: 837–841
   PubMed Web of Science ®Google Scholar
• Uchida T., Kinoshita T., Nagai H., Nakahara Y., Saito H., Hotta T., Murate T. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997; 90: 1403–1409
   PubMed Web of Science ®Google Scholar
• Quesnel B., Guillerm G., Vereecque R., Wattel E., Preudhomme C., Bauters E., Vanrumbeke M., Fenaux P. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985–2990
   PubMed Web of Science ®Google Scholar
• Jonveaux P., Fenaux P., Quiquandon I., Pignon J. M., Lai J. L., Loucheux-Lefebvre M.H., Goossens M., Bauters F., Berger R. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 1991; 6: 2243–2247
   PubMed Web of Science ®Google Scholar
• Sugimoto K., Hirano N., Toyoshima H., Chiba S., Mano H., Takaku F., Yazaki Y., Hirai H. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993; 81: 3022–3026
   PubMed Web of Science ®Google Scholar
• Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148–3157
   PubMed Web of Science ®Google Scholar
• Ben Yehuda D., Krichevsky S., Caspi O., Rund D., Polli-Ack A., Abeliovich D., Zelig O., Yahalom V., Paltiel O., Or R., Peretz T., Ben Neriah S., Yehuda O., Rachmilewitz E. A. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996; 88: 4296–4303
   PubMed Web of Science ®Google Scholar
• Maheswaran S., Englert C., Bennett P., Heinrich G., Haber D. A. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes and Development 1995; 9: 2143–2156
   PubMed Web of Science ®Google Scholar
• Tamaki H., Ogawa H., Ohyashiki K., Ohyashiki J. H., Iwama H., Inoue K., Soma T., Oka Y., Tatekawa T., Oji Y., Tsuboi A., Kim E. H., Kawakami M., Fuchigami K., Tomonaga M., Toyama K., Aozasa K., Kishimoto T., Sugiyama H. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999; 13: 393–399
   PubMed Web of Science ®Google Scholar
• Preudhomme C., Quesnel B., Vachee A., Lepelley P., Collyn D'Hooghe M., Wattel E., Fenaux P. Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. Leukemia 1993; 7: 1291–1293
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos C.E., Yang Y., Deleon E., McCown P., Stass S. A., Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617–2623
   PubMed Web of Science ®Google Scholar
• Shetty V., Mundle S., Alvi S., Showel M., Broady-Rob-Inson L., Dar S., Borok R., Showel J., Gregory S., Rifkin S., Gezer S., Parcharidou A., Venugopal P., Shah R., Hernandez B., Klein M., Alston D., Robin E., Dominquez C., Raza A. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leukemia Research 1996; 20: 891–900
   PubMed Web of Science ®Google Scholar
• Bincoletto C., Saad S. T., Soares Da Silva E., Queiroz M. L. Autonomous proliferation and bcl-2 expression involving haematopoietic cells in patients with myelodysplastic syndrome. British Journal of Cancer 1998; 78: 621–624
   PubMed Web of Science ®Google Scholar
• Parker J. E., Fishlock K. L., Pagliuca A., Mufti G. J. The role of apoptosis, proliferation and amifostine in the myelodysplastic syndromes (MDS) and AML secondary to MDS. Blood 1998; 92: 418a
   Web of Science ®Google Scholar
• Merchav S., Wagemaker G., Souza L. M., Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors. Leukemia 1991; 5: 340–346
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. British Journal of Haematology 1995; 89: 67–71
   PubMed Web of Science ®Google Scholar
• Silva M., Grillot D., Benito A., Richard C., Nunez G., Fernandez-Luna J.L. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996; 88: 1576–1582
   PubMed Web of Science ®Google Scholar
• Squadrito F., Altavilla D., Squadrito G., Campo G. M., Arlotta M., Quartarone C., Saitta A., Caputi A. P. Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. British Journal of Pharmacology 1999; 127: 482–488
   PubMed Web of Science ®Google Scholar
• Hellstrom-Lindberg E., Forsblom A. M., Syruckova Z., Christensen B. Effects of G-CSF, EPO, SCF, ATRA and the CD 95 blocking antibody f(ab') 2 on in vitro apoptosis and proliferation in myelodysplastic (MDS) bone marrow. Blood 1997; 90: 521a
   Google Scholar
• Hellstrom-Lindberg E., Ahlgren T., Beguin Y., Carlsson M., Carneskog J., Dahl I. M., Dybedal I., Grimfors G., Kanter-Lewensohn L., Linder O., Luthman M., Lofven-Berg E., Nilsson-Ehle H., Samuelsson J., Tangen J. M., Winqvist I., Oberg G., Osterborg A., Ost A. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92: 68–75
   PubMed Web of Science ®Google Scholar
• Economopoulos T., Mellou S., Papageorgiou E., Pappa V., Kokkinou V., Stathopoulou E., Pappa M., Raptis S. Treatment of anemia in low-risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. Leukemia 1999; 13: 1009–1012
   PubMed Web of Science ®Google Scholar
• Reza S., Shetty V., Dar S., Qawi H., Raza A. Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes. Journal of Interferon Cytokine Research 1998; 18: 871–877
   PubMed Web of Science ®Google Scholar
• Allen D. A., Breen C., Yaqoob M. M., Macdougall I. C. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. Journal of Investigative Medicine 1999; 47: 204–211
   PubMed Web of Science ®Google Scholar
• Navarro J. F., Mora C., Garcia J., Rivero A., Macia M., Gallego E., Mendez M. L., Chahin P. M. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scandanavian. Journal of Urology Nephrology 1999; 33: 121–144
   PubMed Web of Science ®Google Scholar
• Ganser A., Maurer A., Contzen C., Seipelt G., Ottmann O. G., Schadeck-Gressel C., Kolbe K., Haas R., Zander C., Reutzel R., Hoelzer D. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Annals of Hematology 1996; 72: 237–244
   PubMed Web of Science ®Google Scholar
• Stasi R., Brunetti M., Bussa S., Conforti M., Martin L. S., La Presa M., Bianchi M., Parma A., Pagano A. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clinical Laboratory Haematology 1997; 19: 197–201
   PubMedGoogle Scholar
• Campos L., Sabido O., Viallet A., Piselli S., Guyotat D. Implication of ICE and CPP32 in the in vitro growth defects of committed progenitors from myelodysplastic syndromes. Blood 1997; 90: 521a
   Google Scholar
• Denmeade S. R., Lin X. S., Tombal B., Isaacs JT. Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells. Prostate 1999; 39: 269–279
   PubMed Web of Science ®Google Scholar
• Bossy-Wetzel E., Newmeyer D. D., Green D. R. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO Journal 1998; 17: 37–49
   PubMed Web of Science ®Google Scholar
• Jones P. A., Taylor S. M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20: 85–93
   PubMed Web of Science ®Google Scholar
• Momparler R. L., Dore B. T., Momparler L. F. Effect of 5-aza-2'-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells. Cancer Letters 1990; 54: 21–28
   PubMed Web of Science ®Google Scholar
• Attadia V. Effects of 5-aza-2'-deoxycytidine on differentiation and oncogene expression in the human monoblastic leukemia cell line U-937. Leukemia 1993; 7: 9–16
   PubMed Web of Science ®Google Scholar
• Zagonel V., Lo Re G., Maotta G., Babare R., Sardeo G., Gattei V., De Angelis V., Monfardini S., Pinto A. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavorable myelodysplastic syndromes. Leukemia 1993; 7: 30–35
   PubMed Web of Science ®Google Scholar
• Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C., Andre M., Ferrant A. A phase II study with low dose decitabine, a DNA hypomethylating pyrimidine analogue, in high risk MDS patients. Blood 1998; 92: 632a
   PubMed Web of Science ®Google Scholar
• Silverman L. R. Effects of treatment with Azacytidine in patients with the myelodysplastic syndrome. Leukemia Research 1999; 23: S70
   Google Scholar
• Kornblith A. B., Herndon J. E., II, Silverman L. R., Demakos E. P., Reissig R., Holland J. F., Powell B. L., Decastro C., Ellerton J., Larson R. A., Schiffer C., Holland J.C. (1978) The impact of 5-azacytidine on the quality of life of patients with the myelodysplastic syndrome (MDS) treated in a randomized phase III trial of the Cancer and Leukemia Group B (CALGB). Proceedings of the American Society of Clinical Oncology 1998; 17:49a. 1998
   Google Scholar
• Pineau T., Hudgins W. R., Liu L., Chen L. C., Sher T., Gonzalez F. J., Samid D. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochemical Pharmacology 1996; 52: 659–667
   PubMed Web of Science ®Google Scholar
• Gore S. D., Samid D., Weng L. J. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clinical Cancer Research 1997; 3: 1755–1762
   PubMed Web of Science ®Google Scholar
• Gore S. D., Miller C. B., Weng L. J., Burks K., Griffin C. A., Chen T. L., Smith V., Birke P. J., Grever M., Rowinsky E. K. Clinical development of sodium phenylbutyrate as a putative differentiating agent in myeloid malignancies. Anticancer Research 1997; 17: 3938a
   Google Scholar
• Calabro-Jones P.M., Aguilera J. A., Ward J. F., Smoluk G. D., Fahey R. C. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Research 1988; 48: 3634–3640
   PubMed Web of Science ®Google Scholar
• List A. F., Heaton R., Glinsmann-Gibson B., Capizzi RL. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia 1998; 12: 1596–1602
   PubMed Web of Science ®Google Scholar
• Klimecki W., Heaton R., Glinsmann-Gibson B., List A. Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor growth via polyamine-like effects. Blood 1997; 80: 520a
   Google Scholar
• List A. F. Anti-apoptotic therapy: over-riding the cell death program in MDS. Leukemia Research 1999; 23: S77
   PubMed Web of Science ®Google Scholar
• List A. F., Brasfield F., Heaton R., Glinsmann-Gibson B., Crook L., Taetle R., Capizzi R. Stimulation of Hematopoiesis by Amifostine in Patients With Myelodysplastic Syndrome. Blood 1997; 90: 3364–3369
   PubMed Web of Science ®Google Scholar
• Raza A., Qawi H., Naseer O. B., Dar S., Lisak L., Andric T., Ali S. I., Quadri M., Ahmed B., Venugopal P., Gezer S., Gregory S., Loew J., Robin E., Rifkin S. Cytopenias improve in response to amifostine pen-toxifylline/ciprofloxacin/dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS). Blood 1998; 92: 631a
   Web of Science ®Google Scholar
• Neumeister P., Jager G., Schmidt H., Linkesch W. Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome (MDS) - a pilot study. Leukemia Research 1999; 23: S78
   Google Scholar
• De Planque M.M., Kluin-Nelemans H.C., Van Krieken H.J.M., Kluin P. M., Brand A., Beverstock G. C., Wille-Mze R., Van Rood J.J. Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults. British Journal of Haematology 1988; 70: 55–62
   PubMed Web of Science ®Google Scholar
• Tichelli A., Gratwohl A., Nissen C., Speck B. Late clonal complications in severe aplastic anemia. Leukemia Lymphoma 1994; 12: 167–175
   PubMed Web of Science ®Google Scholar
• Molldrem J. J., Caples M., Mavroudis D., Plante M., Young N. S., Barrett A. J. Antithymocyte globulin for patients with myelodysplastic syndrome. British Journal of Haematology 1997; 99: 699–705
   PubMed Web of Science ®Google Scholar
• Jonasova A., Neuwirtova R., Cermak J., Vozobulova V., Mocikova K., Siskova M., Hochova I. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. British Journal of Haematology 1998; 100: 304–309
   PubMed Web of Science ®Google Scholar
• Molldrem J. J., Jiang Y. Z., Stetler-Stevenson M., Mavroudis D., Hensel N., Barrett A. J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. British Journal of Haematology 1998; 102: 1314–1322
   PubMed Web of Science ®Google Scholar
• Killick S., Marsh J.C.W., Gordon-Smith E.C. In vitro antithymocyte globulin (ATG) stimulation of hemopoietic stem cells: correlation with clinical response in patients with aplastic anemia (AA) and myelodysplastic syndromes (MDS). Blood 1998; 92: 693a
   Web of Science ®Google Scholar